Through the collaboration, Genentech will use genome sequencing and survey data on Parkinson’s disease patients, and 23andMe will then be able to conduct additional research on the data.
“We are incredibly excited to work with Genentech again, and for the potential to make breakthroughs in therapeutic research and treatment for Parkinson’s disease,” said Andy Page, president of 23andMe. “This collaboration is truly emblematic of both companies’ broader vision of improving the human condition through genetic research.”
More articles on genomics:
IBM Watson-powered app to deliver personalized health info
IBM, Cleveland Clinic to use Watson for cancer genomics pilot
Phoenix Children’s Hospital opens pediatric genomic research & precision medicine institute
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.